§ Federal grant opportunity · HT942526ALSRPTIA
DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Defense Health Agency Contracting Activity - DHACA is accepting applications for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award. The deadline is September 30, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Defense Health Agency Contracting Activity - DHACA
- Application deadline
- September 30, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526ALSRPTIA
Program overview
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Defense Health Agency Contracting Activity - DHACA.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 30, 2026, allowing time for registration and validation.
Related grant opportunities
- DoW Breast Cancer, Transformative Breast Cancer Consortium Award
- Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)
- DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
- Analysis
- FY 2024 – 2026 Broad Agency Announcement (BAA), Office of Oceanic and Atmospheric Research (OAR)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.